Cell Signaling Technology

Product Pathways - Cell Cycle / Checkpoint

Thymidylate Synthase (D26G11) Rabbit mAb #5449

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP H M R Hm Mk Endogenous 30 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat  Hm=Hamster  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Thymidylate Synthase (D26G11) Rabbit mAb detects endogenous levels of total Thymidylate Synthase protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to central residues of human Thymidylate Synthase protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using Thymidylate Synthase (D26G11) Rabbit mAb.

IP

IP

Immunoprecipitation of Thymidylate Synthase from Jurkat cell lysate using Thymidylate Synthase (D26G11) Rabbit mAb followed by western blot using the same antibody. Lane 1 is 5% input.

Background

The methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) is an essential step in the formation of thymine nucleotides (1,2, reviewed in 3). This process is catalyzed by thymidylate synthase (TS or TYMS), a homodimer composed of two 30 kDa subunits. TS is an intracellular enzyme that provides the sole de novo source of thymidylate, making it a required enzyme in DNA biosynthesis with activity highest in proliferating cells (1). Being the exclusive source of dTMP, investigators have concluded that TS is also an important target for anticancer agents such as 5-fluorouracil (5-FU) (1-5). 5-FU acts as a TS inhibitor and is active against solid tumors such as colon, breast, head, and neck. Research studies have demonstrated that patients with metastases expressing lower levels of TS have a higher response rate to treatment with 5-FU than patients with tumors that have increased levels of TS (5). Researchers continue to investigate TS expression in different types of cancers (6-10).

  1. Johnston, P.G. et al. (1991) Cancer Res 51, 6668-76.
  2. Aschele, C. et al. (2002) Ann Oncol 13, 1882-92.
  3. Jackman, A.L. and Calvert, A.H. (1995) Ann Oncol 6, 871-81.
  4. Van Triest, B. et al. (2000) J Histochem Cytochem 48, 755-60.
  5. Johnston, P.G. et al. (1994) J Clin Oncol 12, 2640-7.
  6. Kwon, H.C. et al. (2007) Ann Oncol 18, 504-9.
  7. Allegra, C.J. et al. (2002) J Clin Oncol 20, 1735-43.
  8. Allegra, C.J. et al. (2003) J Clin Oncol 21, 241-50.
  9. Tsourouflis, G. et al. (2008) Dig Dis Sci 53, 1289-96.
  10. Kim, S.H. et al. (2009) Am J Clin Oncol 32, 38-43.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products